- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03916627
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
A Multi-Cohort Exploratory Study of Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC
This study is being done to better understand whether or not cemiplimab by itself and in combination with other treatments given prior to surgery will cause your tumor to respond in a beneficial way; whether the drug(s) are safe and what side effects they cause; and other details about how they function in the body. One of the treatments that will be combined cemiplimab is another experimental drug called fianlimab. In this form, cemiplimab and fianlimab will each individually be called "study drug" or "study drugs" when combined.
Cemiplimab (also known as REGN2810) and fianlimab (also known as REGN3767) are both a type of drug called a monoclonal antibody. Antibodies are proteins naturally found in your blood that fight infections. A monoclonal antibody is a special kind of antibody that is manufactured as a medication to target specific proteins in the body that may be involved in your cancer.
- Cemiplimab is a drug that blocks the programmed death receptor 1 (PD-1), a cell receptor on immune cells
- Fianlimab is a drug that blocks the action of a protein called lymphocyte activation gene (LAG)-33 (LAG-3)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Clinical Trials Administrator
- Phone Number: 844-734-6643
- Email: clinicaltrials@regeneron.com
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- Icahn School of Medicine at Mount Sinai
-
Contact:
- Phone Number: 212-824-9472
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Patient must have a known diagnosis of NSCLC, HCC, or HNSCC as defined in the protocol
- Patient must be willing and able to provide blood samples at the indicated time points
- Patient must be willing and able to have excisional or core needle biopsies of tumor prior to initiation of cemiplimab as defined in the protocol
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Patient is determined to be a surgical candidate for resection of their tumor
- Adequate organ and bone marrow function as defined in the protocol
Key Exclusion Criteria:
- Patients who have had any systemic anti-cancer therapy or radiotherapy within 6 months prior to entering the study for their current tumor or a different primary tumor
- Patients whose tumor burden, or pace of tumor growth, in the opinion of the Investigator will not permit delaying surgery
- Patients who have participated in a study of an investigational agent or an investigational device within 4 weeks of study therapy or 5 half-lives (whichever is longer)
- Patients who have had major surgery within 14 days prior to initiation of neoadjuvant Therapy
- Patients with metastatic disease for whom the intent of surgery would not be curative
- Uncontrolled, intercurrent illness as defined in the protocol and as determined by the Investigator
- Is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment
- Has active autoimmune disease that has required systemic treatment in the past 1 year
- Has a known, additional malignancy that is progressing and/or requires active treatment. Exceptions include patients with: basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy; in situ cervical or anal cancer; prostate cancer on stable dose of hormonal therapy without rising prostate-specific antigen (PSA); breast cancer who have been treated with curative intent, who may be on hormonal therapy.
- Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent
- History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to study treatment.
- Uncontrolled infection with human immunodeficiency virus (HIV), HBV or hepatitis C infection (HCV); or diagnosis of immunodeficiency as defined in the protocol
- NSCLC cohorts only: Patients do not have a history of smoking. History of smoking is defined as smoking ≥100 cigarettes in a lifetime.
- NSCLC cohorts only: Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or c-ros oncogene 1 (ROS1) fusions.
Note: Other protocol defined Inclusion/Exclusion criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort B
Cemiplimab prior to surgery; cemiplimab post surgery (HCC)
|
Administered intravenous (IV)
Other Names:
|
Experimental: Cohort B2
SBRT 8 Gy X 3 fractions followed by cemiplimab prior to surgery; cemiplimab post surgery (HCC)
|
Administered intravenous (IV)
Other Names:
|
Experimental: Cohort A1
Cemiplimab prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC) Not open for accrual
|
Administered intravenous (IV)
Other Names:
Administered intravenous (IV)
|
Experimental: Cohort A2
Cemiplimab and platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC) Not open for accrual
|
Administered intravenous (IV)
Other Names:
Administered intravenous (IV)
|
Experimental: Cohort A3
Platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC) Not open for accrual
|
Administered intravenous (IV)
Other Names:
Administered intravenous (IV)
|
Experimental: Cohort C
Cemiplimab prior to surgery; standard of care radiation and/or chemotherapy followed by cemiplimab post surgery (HNSCC) Not open for accrual
|
Administered intravenous (IV)
Other Names:
|
Experimental: Cohort B3
Cemiplimab and fianlimab before and after surgery (HCC)
|
Administered intravenous (IV)
Other Names:
Administered IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major pathologic response (MPR) at time of surgery for the NSCLC cohorts
Time Frame: At time of surgery
|
Cohorts A1, A2, A3
|
At time of surgery
|
Major treatment effect (MTE) at time of surgery is the primary endpoint for the HNSCC cohort
Time Frame: At time of surgery
|
Cohort C
|
At time of surgery
|
Significant tumor necrosis (STN) at time of surgery is the primary endpoint for the HCC cohorts
Time Frame: At time of surgery
|
Cohort B, B2, B3
|
At time of surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease-free survival (DFS)
Time Frame: Up to 60 months following surgery
|
Defined as the time from date of surgery until recurrence of tumor or death from any cause after successful surgery and recovery
|
Up to 60 months following surgery
|
Overall response rate (ORR)
Time Frame: Up to 60 months following surgery
|
Defined as the percent of patients with a complete response (CR) or partial response (PR) documented by the Investigator per RECIST 1.1.
as described in the protocol
|
Up to 60 months following surgery
|
OS rate
Time Frame: 12 months
|
12 months
|
|
OS rate
Time Frame: 18 months
|
18 months
|
|
OS rate
Time Frame: 24 months
|
24 months
|
|
OS rate
Time Frame: 36 months
|
36 months
|
|
OS rate
Time Frame: 48 months
|
48 months
|
|
OS rate
Time Frame: 60 months
|
60 months
|
|
Incidence of treatment emergent adverse events (TEAEs)
Time Frame: Up to 60 months following surgery
|
Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0)
|
Up to 60 months following surgery
|
Incidence of SAEs
Time Frame: Up to 60 months following surgery
|
Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0)
|
Up to 60 months following surgery
|
Incidence of deaths
Time Frame: Up to 60 months following surgery
|
Up to 60 months following surgery
|
|
Incidence of laboratory abnormalities
Time Frame: Up to 60 months following surgery
|
Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0)
|
Up to 60 months following surgery
|
Change in tumor-infiltrating CD8 T-cell density
Time Frame: Baseline to time of surgery
|
Defined as the change from baseline to the time of surgery
|
Baseline to time of surgery
|
Delay to surgery
Time Frame: Surgery >28 days following the end of the cycle of last dose of cemiplimab
|
Defined as surgery >28 days following the end of the second cycle of cohort specific neoadjuvant therapy
|
Surgery >28 days following the end of the cycle of last dose of cemiplimab
|
Event-free survival (EFS)
Time Frame: Up to 60 months following surgery
|
Defined as the time from the first study treatment to the date of disease progression that precluded definitive surgery, or recurrence of tumor after successful surgery, or death from any cause.
|
Up to 60 months following surgery
|
Overall survival (OS)
Time Frame: Up to 60 months following surgery
|
Defined as the time from the first study treatment and date of death for any reason
|
Up to 60 months following surgery
|
Incidence of imAEs
Time Frame: Up to 60 months following surgery
|
Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0)
|
Up to 60 months following surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R2810-ONC-1866
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; American Society of Clinical Oncology; Radiological... and other collaboratorsWithdrawnHepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage... and other conditionsUnited States
Clinical Trials on cemiplimab
-
Ottawa Hospital Research InstituteOntario Institute for Cancer ResearchNot yet recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage...United States
-
Regeneron PharmaceuticalsPacific Pediatric Neuro-Oncology ConsortiumTerminatedHigh Grade Glioma | Diffuse Intrinsic Pontine Glioma | Relapsed Solid Tumor | Refractory Solid Tumor | Relapsed Central Nervous System Tumor | Refractory Central Nervous System TumorUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingRecurrent Skin Squamous Cell Carcinoma | Resectable Skin Squamous Cell Carcinoma | Stage I Skin Cancer | Stage II Skin Cancer | Stage III Skin CancerUnited States
-
Regeneron PharmaceuticalsSanofiNo longer availableCutaneous Squamous Cell Carcinoma
-
H. Lee Moffitt Cancer Center and Research InstituteRegeneron PharmaceuticalsTerminatedCutaneous Squamous Cell Carcinoma of the Head and Neck | Cutaneous Squamous Cell CarcinomaUnited States
-
Reinhard DummerSanofi; Sun Pharmaceutical Industries LtdRecruiting
-
University of MiamiRegeneron PharmaceuticalsWithdrawnHead and Neck Squamous Cell Carcinoma | HNSCC | Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of Hypopharynx
-
Regeneron PharmaceuticalsCompletedAdvanced Cutaneous Squamous Cell CarcinomaUnited States, Spain, France, Italy, Australia, Germany, Brazil, Greece
-
Regeneron PharmaceuticalsActive, not recruitingBasal Cell Carcinoma | Cutaneous Squamous Cell CarcinomaUnited States, Puerto Rico